Trusted Resource for Clinical Trials, Protocols & Progress
Wearables are connected devices worn on the body that collect health-related data. Sensors may be embedded within wearables or used independently to monitor physiological markers. In clinical research, these tools can measure:
Click to read the full article.
Patient no-shows, late arrivals, and missed follow-ups can disrupt clinical trial timelines. Key factors contributing to non-compliance include:
Click to read the full article.
Virtual assistants are AI-enabled tools that simulate human conversation to provide patient support. They can be accessed via mobile apps, websites, or voice assistants like Alexa or Google Assistant. Chatbots are a type of virtual assistant, often text-based, that automate responses to common queries and interactions.
Click to read the full article.
Digital trial platforms are central to decentralized and hybrid clinical trials. They host crucial patient touchpoints such as visit scheduling, symptom logging, reminders, and communication. Tracking how patients interact with these touchpoints reveals:
Click to read the full article.
Patient diaries—also known as eDiaries—are electronic systems that allow trial participants to document their daily health experiences, medication adherence, and any adverse events. Real-time feedback tools include platforms or applications that collect this data instantly and provide two-way communication, enabling clinical teams to act swiftly when issues arise.
Click to read the full article.
Localization goes beyond simple translation. It includes cultural adaptation of language, layout, units of measurement, imagery, date formats, and communication tone. In clinical trial platforms, this may involve:
Click to read the full article.
Engagement tools enhance the trial experience for participants and support sites with real-time data collection and streamlined communication. When implemented effectively, these tools contribute to:
Click to read the full article.
Population heterogeneity impacts disease presentation, drug metabolism, efficacy, and safety profiles. Lack of representation can lead to inaccurate dosing, missed adverse events, and inequitable access to emerging therapies.
Click to read the full article.
Historically, clinical trials have failed to represent populations by age, sex, race, ethnicity, and socioeconomic background. This underrepresentation has real consequences, including adverse drug reactions, limited access to innovations, and public mistrust in healthcare research. Recognizing this, global regulators are increasingly mandating the integration of Diversity, Equity, and Inclusion (DEI) into clinical trial design and conduct.
Click to read the full article.
Eligibility criteria are often criticized for excluding key populations such as the elderly, women of childbearing potential, those with comorbidities, and racial or ethnic minorities. These exclusions not only compromise the external validity of a study but also limit treatment options for those populations post-approval.
Click to read the full article.
